Recent Updates
Recently added Catalysts
PHVS Positive Sentiment

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Wednesday, March 6, 2024 BiopharmaWatch Research 4 min read
Add on Google
Key Takeaway: Pharvaris (Nasdaq: PHVS) has announced the acceptance of abstracts for presentations of clinical data on their oral bradykinin B2 receptor antagonist, Deucrictibant, at two upcoming congresses. These events include the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) in Milan and the 2024 HAE International Regional Conference Americas in Panama City. The data presented will cover various studies including safety, efficacy, and quality of life improvements for patients with hereditary angioedema (HAE). The company aims to provide effective alternatives for managing HAE attacks through their innovative therapeutic approach.
Price reaction · baseline $24.22 (2024-03-05 close) · hit after-hours · clean, no other PHVS news in the window
day 0 close
+5.9%
day 1 · peak
+8.9%
day 3
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pharvaris will present promising clinical data on Deucrictibant at major congresses.
  • The presentations may enhance understanding of HAE treatment options.
  • Pharvaris focuses on developing novel therapies specifically for rare diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+50%
120-day peak, hindsight
Typical move
8.8%
average across 6 past catalysts
Lead asset
Deucrictibant
Phase 3 · Hereditary Angioedema (HAE)

Full Press Release Details

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA), to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas, to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows:
3rd ITACA National Congress, Milan, Italy, March 14-16, 2024.
Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Presenter: Mauro Cancian, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presenter: Giuseppe Spadaro, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Presenter: Andrea Zanichelli, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries
Presenter: Andrea Zanichelli, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Mauro Cancian, M.D., Ph.D.
Format: Selected Oral and Poster Presentation
Date, time: Saturday, March 16, 10:00 a.m. CET (5:00 a.m. EDT)
2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.
Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Presenter: Anete Grumach, M.D., Ph.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presenter: Markus Magerl, M.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Presenter: Marcus Maurer, M.D.
Format: Poster Presentation
Date, time: Friday, March 15, 7:20 p.m. EDT
Title: Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter: Marc A. Riedl, M.D., M.S.
Format: Oral Presentation
Date, time: Saturday, March 16, 9:30 a.m. EDT
Title: Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
Presenter: William Lumry, M.D.
Format: Oral Presentation
Date, time: Saturday, March 16, 11:15 a.m. EDT
The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.
Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.
Executive Director, Head of External and Internal Communications
maggie.beller@pharvaris.com
This press release doesn't contain an email address to contact.

Frequently Asked Questions

What is Pharvaris developing for hereditary angioedema?

Pharvaris is developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks.

When are the upcoming congress presentations scheduled?

The presentations are scheduled for March 14-17, 2024, at two congresses in Milan and Panama City.

Who is presenting at the 3rd ITACA National Congress?

Presenters include Mauro Cancian, Giuseppe Spadaro, and Andrea Zanichelli among others.

What is the focus of the RAPIDe-3 Phase 3 Trial?

The RAPIDe-3 Phase 3 Trial focuses on the efficacy and safety of Deucrictibant for treating hereditary angioedema.

How can I access the presentations and posters?

The posters and presentation slides will be available on the Pharvaris Investors section during the events.

ShareAdd on Google
Tags: PHVS Viatris Investor Conferences Healthcare Pharvaris Deucrictibant hereditary angioedema clinical data Phase 2 trial
Last updated: Mar 6, 2024

Biotech snapshot

Lead asset
DeucrictibantPhase 3
Hereditary Angioedema (HAE) →

Catalyst track record

+50%
best trade around PHVS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for PHVS.

See every catalyst's timing & PoA →